Man Group plc Has $965,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Man Group plc grew its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 342.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 121,792 shares of the company's stock after purchasing an additional 94,263 shares during the period. Man Group plc's holdings in Amneal Pharmaceuticals were worth $965,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Barclays PLC lifted its position in shares of Amneal Pharmaceuticals by 134.1% during the 3rd quarter. Barclays PLC now owns 296,384 shares of the company's stock valued at $2,466,000 after buying an additional 169,756 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Amneal Pharmaceuticals by 16.7% during the 4th quarter. SG Americas Securities LLC now owns 74,518 shares of the company's stock valued at $590,000 after buying an additional 10,674 shares in the last quarter. Janney Montgomery Scott LLC purchased a new position in shares of Amneal Pharmaceuticals during the 4th quarter valued at approximately $121,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its position in shares of Amneal Pharmaceuticals by 13.6% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 46,240 shares of the company's stock valued at $366,000 after buying an additional 5,523 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of Amneal Pharmaceuticals in the fourth quarter worth approximately $520,000. Hedge funds and other institutional investors own 31.82% of the company's stock.

Insider Activity at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.90, for a total transaction of $712,000.00. Following the transaction, the director now directly owns 1,808,886 shares of the company's stock, valued at $16,099,085.40. The trade was a 4.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the business's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $8.35, for a total value of $41,750,000.00. Following the sale, the insider now owns 48,578,209 shares in the company, valued at approximately $405,628,045.15. The trade was a 9.33% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 17.45% of the company's stock.

Amneal Pharmaceuticals Stock Down 1.0%

Shares of NASDAQ AMRX traded down $0.07 during mid-day trading on Wednesday, hitting $7.22. 477,088 shares of the company were exchanged, compared to its average volume of 1,448,967. The stock has a 50 day simple moving average of $7.56 and a 200-day simple moving average of $8.03. Amneal Pharmaceuticals, Inc. has a 1-year low of $6.29 and a 1-year high of $9.48. The firm has a market cap of $2.26 billion, a price-to-earnings ratio of -10.61 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings results on Friday, May 2nd. The company reported $0.19 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.05. The business had revenue of $695.42 million during the quarter, compared to analysts' expectations of $714.78 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. Analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Barclays raised their price objective on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a report on Monday, March 3rd. Wall Street Zen downgraded Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. Finally, JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $9.00 to $12.00 in a research report on Monday, February 24th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Amneal Pharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $11.50.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.